Renalytix Plc (NASDAQ:RNLX) Q1 2023 Earnings Call Transcript

Page 4 of 4

Thomas McLain: Yes. So, our list price for the test is set at $1,200. Our contracts for payment of the test have been at $950 or more.

Yi Chen: Got it. Could you share with us the latest feedback from the FDA regarding the De Novo application? Is the FDA awaiting additional clinical evidence or is the existing clinical evidence submission for the FDA to make a decision?

James McCullough: Fergus?

Fergus Fleming: At this moment in time, the FDA have all the information that they have requested and we provided all the data and analysis that have been requested through the breakthrough process. So, there is no outstanding data requests from the FDA at this moment in time.

Yi Chen: Okay. Thank you.

Operator: Thank you. I’m currently showing no further questions in the queue. Thank you all for participating. This concludes today’s conference call. You may now disconnect.

James McCullough: Thank you.

Follow Renalytix Plc (NASDAQ:RNLX)

Page 4 of 4